APAC For two decades the case for running a clinical trial in Asia was essentially arithmetic: the same study, for less money. That argument has not gone away, but it is no longer the one APAC’s own CRO leaders make. Asia Pacific is now the only region in the world where…
Hong Kong Hong Kong is repositioning itself within the global innovation landscape, moving beyond its total market-driven model to take an industry policy oriented market-driven approach. Through Office for Attracting Strategic Enterprises (OASES), the government is working to attract leading companies from overseas and Chinese Mainland in fields such as life and…
Asia-Pacific Translating scientific breakthroughs into products that genuinely impact patients is more challenging than it has ever been. Only ten percent of drugs that enter clinical trials ever make it all the way to patients, meaning that much of the USD 250 billion spent on pharma R&D every year goes towards…
Hong Kong Dr Jeremy Teoh of the Chinese University of Hong Kong leads a research programme spanning bladder cancer biology, surgical innovation, and translational science. From building what is believed to be Asia’s first bladder cancer organoid biobank to chairing multicentre trials that have earned top honours from the European Association of…
Hong Kong When, in his 2023 policy address, Hong Kong Chief Executive John Lee announced the territory’s intention to conduct its own primary reviews of medicines, the initial industry reaction was mixed. The legitimate questions of what this updated regulator would do, and whom it would serve, swirled, with many Western multinationals…
Hong Kong After a rocky couple of years, Hong Kong has defied its sceptics and definitively bounced back. As Asia’s financial capital and the bridge between mainland China and international markets, the global stock market slump between 2021 and 2024 had an outsized impact on Hong Kong, with sluggish GDP growth and…
Hong Kong It is not unreasonable, at first glance, to ask why so many pharma multinationals have chosen to establish standalone affiliates in Hong Kong. After all, only 7.5 million people call Hong Kong home, putting a cap on growth potential, and it could easily be covered by affiliates based in the…
Hong Kong Hong Kong – already Asia’s finance hub and an increasingly robust life science R&D destination – is placing huge bets on becoming the region’s prime location for developing, financing, and scaling robotics technology. In 2019, Roy Long Hei, founder and CEO of Robocore, returned to Hong Kong from Silicon…
Hong Kong Hong Kong’s biotech capital market has completed one of the more dramatic reversals in recent years. After a brutal two-year drought in which valuations collapsed, liquidity evaporated, and companies were forced to sell assets just to survive, the market roared back in 2025 – reclaiming the top global position for…
Hong Kong In 2026, regulation, policy, institutions, and expertise are aligning to ensure Hong Kong can be a player in an extremely competitive Asian clinical trials landscape. From real-world data studies to groundbreaking early-stage work in vaccines, oncology, and even cell therapy, as well as some later-stage studies for niche indications, both…
Hong Kong Amgen’s trajectory in Hong Kong reflects a broader shift underway across the territory’s healthcare landscape, where data-driven care and cross-sector collaboration are converging to accelerate access to innovation. Against the backdrop of rapid demographic change and rising chronic disease burden, Kara Cheung outlines how the company is evolving its portfolio,…
Hong Kong Xia JIN, co-founder & CEO of Hong Kong-based immunology biotech Immuno Cure, outlines the progress of its DNA vaccine platform, highlighting strong Phase I results for an HIV therapeutic vaccine and upcoming Phase II trials. He discusses regulatory and operational challenges in China, growing institutional support, partnership efforts, and expansion…
See our Cookie Privacy Policy Here
